Possis Medical seeks US clearance to sell Perma-Seal Graft

US cardiovascular device manufacturer Possis Medical Inc is seeking clearance from the US Food and Drug Administration (FDA) to begin selling its Perma-Seal(c) graft in the United States. The Perma-Seal dialysis access graft is designed to provide kidney dialysis patients with the option of synthetic vascular access with needle sealing capability, in order to minimise bleeding, shorten dialysis sessions and allow early graft use without the need for temporary catheter utilisation.

The Minnesota-based company hopes the FDA will come to a decision before the end of …